Bedrijfsoverzicht
Akanda Corp. is a specialized entity within the healthcare sector, specifically operating in the drug manufacturing industry for specialty and generic pharmaceuticals, although its operational focus as of August 21, 2025, involves the cultivation, manufacture, and distribution of cannabis-based products through its subsidiaries. The company was originally incorporated in 2021 and is headquartered in an unspecified location, having undergone a significant structural change where it was acquired by First Towers & Fiber Corp. via a reverse merger transaction. As of the latest available data, the enterprise is valued at a market capitalization of $334,546, generating a trailing twelve-month revenue of $836,664. The employee count is listed as N/A, indicating that specific personnel data is not disclosed in the current financial reporting. These valuation figures suggest the company operates on a very small scale relative to its peers in the broader healthcare and cannabis markets, reflecting a micro-cap status where liquidity and market depth may be constrained compared to larger industry participants.
Financiële gezondheid
The financial statements for the trailing twelve months reveal a revenue stream of $836,664, which stands in stark contrast to a net income of $-2,395,394, highlighting a substantial disconnect between top-line sales and bottom-line profitability. This significant gap indicates a cost structure characterized by high operating expenses or losses that far exceed gross revenue, resulting in a net loss that is more than double the annual revenue. Furthermore, the company reports an EBITDA of $-3,678,018, which underscores that even before interest, taxes, depreciation, and amortization, the core business operations are generating negative cash earnings. The free cash flow stands at $-4,874,154, a metric that signals a complete lack of financial flexibility for capital expenditures, debt repayment, or dividend distributions without external financing. Profitability is severely challenged across all margin metrics, with a gross margin of 24.9%, an operating margin of -443.8%, and a profit margin of -266.3%, illustrating that the company is losing money on every dollar of sales generated. Liquidity management presents a mixed picture; while the company holds $2.52M in cash against $391,241 in debt, the debt-to-equity ratio of 11.85 indicates a highly leveraged balance sheet where equity is minimal relative to obligations. The current ratio of 1.25 suggests the company maintains just enough current assets to cover its current liabilities, providing a narrow buffer for short-term liquidity needs. Return metrics reflect the negative financial position, with a return on equity of -60.9% and a return on assets of -28.7%, revealing that management is currently destroying value rather than generating returns for shareholders or utilizing assets efficiently.
Waarderingsbeoordeling
Valuation multiples for Akanda Corp. present unique characteristics due to the absence of positive earnings, with a trailing P/E ratio of 0.00 and a forward P/E listed as N/A. The zero trailing P/E confirms that earnings per share are negative, rendering the traditional price-to-earnings metric inapplicable for assessing value based on profitability growth. The price-to-book ratio is recorded at 0.03, which indicates that the market capitalization is only 3% of the company's book value, suggesting the stock trades at a significant discount to its accounting net asset value. Alternative valuation metrics provide further context, with a price-to-sales ratio of 0.40 and an EV/EBITDA of 0.56, both figures implying a very low price relative to revenue and earnings power, though these metrics must be interpreted with caution given the losses. The stock price has experienced extreme volatility within the reporting period, ranging between a 52-week low of $0.51 and a 52-week high of $46.45. Without a specific current share price provided in the facts to calculate the exact percentage, the trading range demonstrates a massive spread where the stock could theoretically be trading anywhere within this wide band relative to historical extremes. The beta value of 1.73 indicates that the stock is significantly more volatile than the broader market, moving 73% more than the market average, which introduces substantial risk for risk-averse investors.
Growth & Income
Growth metrics for the company are currently unavailable, with revenue growth year-over-year listed as N/A and earnings growth year-over-year listed as N/A. The absence of growth data prevents a direct comparison between the pace of revenue expansion and earnings performance, leaving the trajectory of profitability unclear. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning no portion of earnings is distributed to shareholders. Instead of providing income through dividends, the company effectively reinvests its limited resources or relies on external capital to fund operations and growth initiatives. The overall growth and income profile is defined by the lack of historical growth data and the complete absence of dividend income, positioning the equity as a speculative instrument rather than an income-generating asset.